Skip to Main Content

A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)

Conditions

COVID-19 Inpatient | COVID-19 Outpatient

Phase COVID-III

What is the purpose of this trial?

This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.

  • Ages
    12 years and older
  • Gender
    Both
Find out more about who can participate in this trial
  • Trial with
    Genentech, Inc.
  • Start Date
    09/23/2020
  • End Date
    07/30/2020
Trial Image

For more information about this study, contact:

Laurie Andrews

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sub-Investigator

  • Last Updated
    10/01/2020
  • Study HIC
    #2000028556

Contact Information

For more information about this study, including how to volunteer, contact Laurie Andrews

Volunteer Now